BR112012008221A2 - compostos heterocíclicos e uso dos mesmos como antagonistas do receptor ccr2 - Google Patents

compostos heterocíclicos e uso dos mesmos como antagonistas do receptor ccr2

Info

Publication number
BR112012008221A2
BR112012008221A2 BR112012008221A BR112012008221A BR112012008221A2 BR 112012008221 A2 BR112012008221 A2 BR 112012008221A2 BR 112012008221 A BR112012008221 A BR 112012008221A BR 112012008221 A BR112012008221 A BR 112012008221A BR 112012008221 A2 BR112012008221 A2 BR 112012008221A2
Authority
BR
Brazil
Prior art keywords
receptor antagonists
heterocyclic compounds
ccr2 receptor
ccr2
heterocyclic
Prior art date
Application number
BR112012008221A
Other languages
English (en)
Portuguese (pt)
Inventor
Alfred Binggeli
Guido Hartmann
Hans P Maerki
Johannes Aebi
Luke Green
Patrizio Mattei
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012008221A2 publication Critical patent/BR112012008221A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112012008221A 2009-10-07 2010-10-05 compostos heterocíclicos e uso dos mesmos como antagonistas do receptor ccr2 BR112012008221A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172408 2009-10-07
PCT/EP2010/064770 WO2011042399A1 (en) 2009-10-07 2010-10-05 Bicyclic heterocycles and their use as ccr2 receptor antagonists

Publications (1)

Publication Number Publication Date
BR112012008221A2 true BR112012008221A2 (pt) 2016-03-08

Family

ID=43105073

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008221A BR112012008221A2 (pt) 2009-10-07 2010-10-05 compostos heterocíclicos e uso dos mesmos como antagonistas do receptor ccr2

Country Status (13)

Country Link
US (1) US8471004B2 (enExample)
EP (1) EP2486042B1 (enExample)
JP (1) JP5559336B2 (enExample)
KR (1) KR101451487B1 (enExample)
CN (1) CN102574858B (enExample)
AU (1) AU2010305495A1 (enExample)
BR (1) BR112012008221A2 (enExample)
CA (1) CA2774215A1 (enExample)
ES (1) ES2455266T3 (enExample)
IL (1) IL217965A0 (enExample)
IN (1) IN2012DN00764A (enExample)
MX (1) MX2012002390A (enExample)
WO (1) WO2011042399A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
WO2020033791A1 (en) 2018-08-09 2020-02-13 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
CN111423454B (zh) * 2020-04-24 2021-06-22 苏州大学 哌嗪类化合物及其在制备趋化因子受体ccr2拮抗剂中的应用
CN113979889A (zh) * 2021-11-09 2022-01-28 西安康福诺生物科技有限公司 一种双官能化聚乙二醇基胺的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3740256A1 (de) 1987-05-14 1988-12-08 Bayer Ag Thiazolo-hydantoine
WO2002070523A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
CA2516705A1 (en) * 2003-02-24 2004-09-10 Merck & Co., Inc. Aminocyclopentyl fused heterotricylicamide modulators of chemokine receptor activity
EP1756089B1 (en) * 2004-05-26 2008-10-22 Janssen Pharmaceutica N.V. Mercaptoimidazoles as ccr2 receptor antagonists
EP1858515A2 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
KR101176697B1 (ko) * 2006-04-20 2012-08-23 에프. 호프만-라 로슈 아게 케모카인 수용체의 다이아제판 유도체 조절자
CA2695998A1 (en) 2007-07-19 2009-01-22 F. Hoffmann-La Roche Ag Novel heterocyclyl compounds
MX2010003621A (es) 2007-10-01 2010-04-14 Hoffmann La Roche N-heterociclil biaril carboxamidas como antagonistas del receptor ccr.

Also Published As

Publication number Publication date
JP5559336B2 (ja) 2014-07-23
EP2486042B1 (en) 2014-01-22
IN2012DN00764A (enExample) 2015-06-26
ES2455266T3 (es) 2014-04-15
US20110082294A1 (en) 2011-04-07
US8471004B2 (en) 2013-06-25
IL217965A0 (en) 2012-03-29
AU2010305495A1 (en) 2012-03-15
MX2012002390A (es) 2012-04-02
EP2486042A1 (en) 2012-08-15
CN102574858B (zh) 2015-06-24
KR20120051090A (ko) 2012-05-21
KR101451487B1 (ko) 2014-10-15
CN102574858A (zh) 2012-07-11
WO2011042399A1 (en) 2011-04-14
JP2013506701A (ja) 2013-02-28
CA2774215A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
HUS2200033I1 (hu) CGRP receptor antagonisták
PL2513093T3 (pl) Nowi antagoniści receptora CCR2 i ich zastosowanie
BRPI0817245A2 (pt) Derivados e quinolina como antagonistas receptores de 5ht5a
HRP20190016T1 (hr) Heterociklički spojevi i njihova upotreba
BRPI1015315A2 (pt) composto heterocíclico fundido e uso dos mesmos
BRPI0821141A2 (pt) Derivados de heteroarila como antagonistas do receptor de orexina
BRPI0812981A2 (pt) Derivados de piperidina úteis como antagonistas dos receptores de orexina
BRPI0919844A2 (pt) compostos de azaindazol como antagonistas do receptor ccr1
BRPI0919539A2 (pt) antagonistas de receptor de opioide periférico e empregos dos mesmos
BRPI0717023A2 (pt) Tiazol pirazolopirimidina como antagonistas do receptor de crf1
BRPI1015145A2 (pt) derivados de tiazol e seu uso como receptores antagonistas de p2y12
BRPI0815349A2 (pt) 6-amino-5-cloro-4-pirimidinacarboxilatos substituídos com 2-(2-fluorofeni-la) e seu uso como herbicidas
BR112013016030A2 (pt) compostos e seu uso como inibidores de bace
BRPI1016189A2 (pt) compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2
ATE540942T1 (de) Imidazolderivate als ccr2-rezeptor-antagonisten
BRPI0909157A2 (pt) compostos heterocíclicos como antagonistas de receptores de adenosina
BRPI0817061A2 (pt) Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3
CR20130360A (es) Compuesto heterocíclico y su uso
BRPI0815948A2 (pt) "compostos heterocíclicos como antagonistas de receptorncrth2"
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
BR112013004662A2 (pt) agonistas de receptores de neurotrofina e o uso destes como medicamentos
BRPI0820701A2 (pt) Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
BRPI0814767A2 (pt) Derivados de monoamida como antagonistas do receptor de orexina
CU23857B1 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina
BRPI0921669A2 (pt) piperazina de arila e seu uso como antagonistas alfa 2c

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]